FDA批准了Athos Therapeutics关于新口服药物ATH-063的二期临床试验，用于治疗严重溃疡性结肠炎。 FDA approves Athos Therapeutics' Phase 2 trial for new oral drug ATH-063 to treat severe ulcerative colitis.

雅索斯治疗公司已获得FDA批准, 启动ATH-063的第二阶段临床试验, Athos Therapeutics has received FDA approval to launch a Phase 2 clinical trial for ATH-063, an oral, first-in-class drug targeting moderately to severely active, biologic-refractory ulcerative colitis. 使用AthosOmics.A.A.A.A.平台开发的该药物,旨在通过监管紧凑接合蛋白质,减少炎症,促进肠道愈合。 The drug, developed using the company’s AthosOmics.AI platform, aims to reduce inflammation and promote intestinal healing by regulating tight junction proteins. 试验将评估安全性和有效性,同时利用AI驱动的多组分析,对超过35 000个病人样本进行分析,以验证药物机制并指导未来的发展。 The trial will assess safety and efficacy while using AI-driven multi-omic analysis of over 35,000 patient samples to validate the drug’s mechanism and guide future development.